NewAmsterdam Pharma (NAMS) Enterprise Value (2022 - 2025)
Historic Enterprise Value for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to -$702.9 million.
- NewAmsterdam Pharma's Enterprise Value fell 6628.76% to -$702.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$702.9 million, marking a year-over-year decrease of 6628.76%. This contributed to the annual value of -$834.2 million for FY2024, which is 14502.57% down from last year.
- NewAmsterdam Pharma's Enterprise Value amounted to -$702.9 million in Q3 2025, which was down 6628.76% from -$739.2 million recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma's Enterprise Value peaked at -$417597.0 during Q2 2023, and registered a low of -$834.2 million during Q4 2024.
- For the 4-year period, NewAmsterdam Pharma's Enterprise Value averaged around -$501.4 million, with its median value being -$444.4 million (2022).
- In the last 5 years, NewAmsterdam Pharma's Enterprise Value soared by 2390.49% in 2023 and then crashed by 10303962.52% in 2024.
- NewAmsterdam Pharma's Enterprise Value (Quarter) stood at -$447.4 million in 2022, then increased by 23.9% to -$340.4 million in 2023, then crashed by 145.03% to -$834.2 million in 2024, then increased by 15.73% to -$702.9 million in 2025.
- Its last three reported values are -$702.9 million in Q3 2025, -$739.2 million for Q2 2025, and -$808.5 million during Q1 2025.